Q4 2017 13F Holders as of 12/31/2017
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
108M
-
Number of holders
-
104
-
Total 13F shares, excl. options
-
24.2M
-
Shares change
-
+6.73M
-
Total reported value, excl. options
-
$464M
-
Value change
-
+$126M
-
Put/Call ratio
-
0.75
-
Number of buys
-
69
-
Number of sells
-
-25
-
Price
-
$19.22
Significant Holders of Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA) as of Q4 2017
126 filings reported holding NTLA - Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q4 2017.
Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA) has 104 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 24.2M shares
of 108M outstanding shares and own 22.41% of the company stock.
Largest 10 shareholders include FMR LLC (4.29M shares), Atlas Venture Associates IX, LLC (3.58M shares), ORBIMED ADVISORS LLC (2.34M shares), Vanguard Group Inc (1.84M shares), BlackRock Inc. (1.71M shares), ARK Investment Management LLC (1.38M shares), STATE STREET CORP (1.16M shares), BAKER BROS. ADVISORS LP (1.15M shares), FARALLON CAPITAL MANAGEMENT LLC (1.14M shares), and Temasek Holdings (Private) Ltd (791K shares).
This table shows the top 104 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.